{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:08Z","timestamp":1792839668030,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017618","name":"Division of Diabetes, Endocrinology, and Metabolic Diseases","doi-asserted-by":"publisher","award":["U01DK065184"],"award-info":[{"award-number":["U01DK065184"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40264-024-01486-6","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:02:03Z","timestamp":1727193723000},"page":"151-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-6066","authenticated-orcid":false,"given":"Vincent L.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don C.","family":"Rockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar S.","family":"Bjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiman","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Hoofnagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Drug-Induced Liver Injury Network Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"issue":"2","key":"1486_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/jhep.2002.34857","volume":"36","author":"C Sgro","year":"2002","unstructured":"Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451\u20135.","journal-title":"Hepatology"},{"issue":"7","key":"1486_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","volume":"144","author":"ES Bjornsson","year":"2013","unstructured":"Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419\u201325 (25 e1-3; quiz e19-20).","journal-title":"Gastroenterology"},{"key":"1486_CR3","doi-asserted-by":"crossref","unstructured":"Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, et al. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology. 2019 Jun;156(8):2230-41 e11.","DOI":"10.1053\/j.gastro.2019.02.002"},{"issue":"8","key":"1486_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","volume":"24","author":"MB De Valle","year":"2006","unstructured":"De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1486_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","volume":"58","author":"FJ de Abajo","year":"2004","unstructured":"de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58(1):71\u201380.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1486_CR6","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/ajg.2012.138","volume":"107","author":"KT Suk","year":"2012","unstructured":"Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012;107(9):1380\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1486_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.","journal-title":"BMC Med"},{"issue":"6","key":"1486_CR8","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/hep.23937","volume":"52","author":"A Reuben","year":"2010","unstructured":"Reuben A, Koch DG, Lee WM, Acute Liver Failure Study G. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065\u201376.","journal-title":"Hepatology"},{"issue":"3","key":"1486_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2796.2007.01818.x","volume":"262","author":"G Wei","year":"2007","unstructured":"Wei G, Bergquist A, Broome U, Lindgren S, Wallerstedt S, Almer S, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med. 2007;262(3):393\u2013401.","journal-title":"J Intern Med"},{"issue":"7","key":"1486_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340\u201352.","journal-title":"Gastroenterology"},{"issue":"1","key":"1486_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-induced liver injury network (DILIN) prospective study. Drug Saf. 2009;32(1):55\u201368.","journal-title":"Drug Saf"},{"key":"1486_CR12","unstructured":"Machlin SR. Design, methods, and field results of the 1996 medical expenditure panel survey, medical provider component: US Department of Health and Human Services, Public Health Service, Agency; 2000."},{"issue":"6","key":"1486_CR13","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117\u201326.","journal-title":"Hepatology"},{"issue":"12","key":"1486_CR14","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.2105\/AJPH.2021.306534","volume":"111","author":"SH Zuvekas","year":"2021","unstructured":"Zuvekas SH, Kashihara D. The impacts of the COVID-19 pandemic on the medical expenditure panel survey. Am J Public Health. 2021;111(12):2157\u201366.","journal-title":"Am J Public Health"},{"issue":"2","key":"1486_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40264-022-01255-3","volume":"46","author":"A Suzuki","year":"2023","unstructured":"Suzuki A, Tillmann H, Williams J, Hauser RG, Frund J, Suzuki M, et al. Assessment of the frequency, phenotypes, and outcomes of acute liver injury associated with amoxicillin\/clavulanate in 1.4 million patients in the veterans health administration. Drug Saf. 2023;46(2):129\u201343.","journal-title":"Drug Saf"},{"issue":"2","key":"1486_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cpt.2930","volume":"114","author":"S Gu","year":"2023","unstructured":"Gu S, Rajendiran G, Forest K, Tran TC, Denny JC, Larson EA, et al. Drug-induced liver injury with commonly used antibiotics in the all of us research program. Clin Pharmacol Ther. 2023;114(2):404\u201312.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1486_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamainternmed.2024.1836","volume":"184","author":"J Torgersen","year":"2024","unstructured":"Torgersen J, Mezochow AK, Newcomb CW, Carbonari DM, Hennessy S, Rentsch CT, et al. Severe acute liver injury after hepatotoxic medication initiation in real-world data. JAMA Intern Med. 2024;184(8):943\u201352.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"1486_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s11901-019-00475-z","volume":"18","author":"ES Bj\u00f6rnsson","year":"2019","unstructured":"Bj\u00f6rnsson ES. Global epidemiology of drug-induced liver injury (DILI). Current Hepatology Reports. 2019;18(3):274\u20139.","journal-title":"Current Hepatology Reports."},{"issue":"9","key":"1486_CR19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/liv.15262","volume":"42","author":"X Li","year":"2022","unstructured":"Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022;42(9):1999\u20132014.","journal-title":"Liver Int"},{"issue":"7","key":"1486_CR20","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","volume":"41","author":"AK Daly","year":"2009","unstructured":"Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe\u2019er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"1486_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jhep.2017.03.010","volume":"67","author":"TJ Urban","year":"2017","unstructured":"Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, et al. Minocycline hepatotoxicity: clinical characterization and identification of HLA-B *35:02 as a risk factor. J Hepatol. 2017;67(1):137\u201344.","journal-title":"J Hepatol"},{"issue":"5","key":"1486_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","volume":"152","author":"P Nicoletti","year":"2017","unstructured":"Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152(5):1078\u201389.","journal-title":"Gastroenterology"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01486-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01486-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01486-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:05:28Z","timestamp":1738332328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01486-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01486-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"4 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vincent L. Chen has received grants from KOWA, Ipsen, and AstraZeneca (paid to his institution). Einar S. Bjornsson is a member of hepatic assessment committees for clinical trials organized by Novo Nordisk, Sanofi, and Novartis. Don C. Rockey is a member of the hepatic assessment committees for three clinical trials, one each organized by High Tide, Takeda, and Xeris. Huiman Barnhart and Jay H. Hoognagle have no conflicts of interest to report relative to this work. The authors have fully considered non-financial interests, including professional interests and personal relationships\/beliefs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Research reported in this publication was supported by the NIDDK of the National Institutes of Health under award numbers U01DK065211 (Indiana University), U01DK065184 (University of Michigan), U01DK065201 (University of North Carolina-Chapel Hill), U01DK083020 (University of Southern California), U01DK083027 (Thomas Jefferson University\/Albert Einstein Medical Center), U01DK100928 (Icahn School of Medicine at Mount Sinai), and U24DK065176 (Duke University). Additional support is provided by the intramural programs of the NIDDK and National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All DILIN participants provided written informed consent for enrollment, and the procedures were approved by the Institutional Review Boards of the individual DILIN sites and a Data Safety and Monitoring Board appointed by the NIDDK. MEPS protocols were approved by the Westat Institutional Review Board under a multi-project assurance granted by the Office for Protection from Research Risks. All study procedures were compliant with good clinical practice and the Declarations of Helsinki and Istanbul.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All DILIN participants provided written informed consent for enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Individual-level DILIN data cannot be made available due to research participant privacy restrictions. MEPS data are publicly available for download at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of DATA"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"VLC: Data collection, data analysis, drafting of the manuscript. DCR: Data analysis, critical review of the manuscript. HB: Data analysis, critical review of the manuscript. ESB: Data analysis, critical review of the manuscript. JHH: Study conceptualization, data collection, data analysis, critical review of the manuscript. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}